The tolerance and diagnostic efficacy of a new nonionic, intravenous MRI contrast medium, gadodiamide injection (Omniscan®) are reported and compared with those of gadolinium-DOTA after completion of a double-blind, randomized, parallel study in 60 patients using a dose of 0.1 mmol/kg. Two patients were excluded from the statistical analysis after trial entrance since no contrast medium was injected. The indications for the MRI examination were known or suspected CNS lesions. Vital signs, chemical and haematological parameters were monitored. No significant abnormalities were observed, confirming the excellent tolerance of both contrast media. The usefulness of gadolinium-containing contrast media was again documented, since in 8.6% (5/58) of the patients the lesion(s) could be seen only after injection. Contrast enhancement was seen in 87.8% (43/49) of the patients with abnormal findings, and provided additional diagnostic information in 24.5% (12/49). Lack of contrast enhancement in 12.2% (6/49) of patients with abnormal findings was a significant negative finding.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Roman-Goldstein SM, Barnett PA, McCormick CI, Ball MJ, Ramsey F, Neuwelt EA (1991) Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption: toxicity and MR imaging findings. AJNR 12:885–890
Weinmann HJ, Brasch RC, Press WR, Wesbey GE (1984) Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR 142:619–624
Laniado M, Weinmann HJ, Schörner W, Felix R, Speck U (1984) First use of gadolinium-DTPA/dimeglumine in man. Physiol Chem Phys Med NMR 16:157–165
Sze G (1990) New applications of MR contrast agents in neuroradiology. Neuroradiology 32:421–438
Schörner W, Laniado M, Niendorf HP, Schubert C, Felix R (1986) Time-dependent changes in image contrast in brain tumors after gadolinium-DTPA. AJNR 7:1013–1020
Parizel PM, Degryse HR, Ghevens J, et al (1989) Gadolinium-DOTA-enhanced MR imaging of intracranial lesions. J Comput Assist Tomogr 13:378
Post MJD, Sze G, Quencer RN, et al (1990) Gadolinium-enhanced MR in spinal infection. J Comput Assist Tomogr 14:721–729
Ross JS, Modic MT, Masaryk TJ, et al (1989) Assessment of extradural degenerative disease with Gd-DTPA-enhanced MR imaging: correlation with surgical and pathologic findings. AJNR 10:1243–1249
Crain MR, Yuh WTC, Greene GM, Loes DJ, Ryals TJ, Sato Y, Hart MN (1991) Cerebral ischemia: evaluation with contrast-enhanced MR imaging. AJR 157:575–583
Parizel PM, Balériaux D, Rodesch G, et al (1989) Gadolinium-DTPA-enhanced MR imaging of spinal tumors. AJNR 10:249–258
Valk J (1988) Gd-DTPA in MR of spinal lesions. AJR 150:1163–1168
Chamberlain MC, Sandy AD, Press GA (1991) Spinal cord tumors: gadolinium-DTPA-enhanced MR imaging. Neuroradiology 33:469–474
Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W (1991) Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med 22:222–228
Goldstein HA, Kashanian FK, Blumetti RF, Holyoak WL, Hugo FP, Blumenfield DM (1990) Safety assessment of gadopentetate dimeglumine in U.S. clinical trials. Radiology 174:17–23
Salonen OLM (1990) Case of anaphylaxis and four cases of allergic reaction following Gd-DTPA administration. J Comput Assist Tomogr 14:912–913
Tishler S, Hoffman JC (1990) Anaphylactoid reactions to IV gadopentetate dimeglumine. AJNR 11:1167
Harbury OL (1991) Generalized seizure after IV administration of gadopentetate dimeglumine. AJNR 12:666
Chang CA, Sieving PF, Watson AD, Dewey TM, Karpishin TB, Raymond KN, et al (1992) Ionic versus nonionic MR imaging contrast media: operational definitions. J Magn Reson Imaging 2:95–98
O'Toole M, Van Wagoner M, Broschart JL, Prasad R, Leese PT, Quay SC (1989) Non-ionic MRI contrast agents: a phase I clinical trial of the safety and tolerance of S 041 injection. Magn Reson Imaging 7 [Suppl 1]:134
Kaplan GD, Aisen AM, Aravapalli SR (1991) Preliminary clinical trial of gadodiamide injection: a new nonionic gadolinium contrast agent for MR imaging. J Magn Reson Imaging 1:57–62
Van Wagoner M, O'Toole M, Worah D, Leese PT, Quay SC (1991) A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest Radiol 26:980–986
Greco A, McNamara MT, Lanthiez P, Quay SC, Michelozzi G (1990) Gadodiamide injection: nonionic gadolinium chelate for MR imaging of the brain and spine — phase II–III clinical trial. Radiology 176:451–456
Sze G, Brant-Zawadzki M, Haughton VM, et al (1991) Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 181:693–699
About this article
Cite this article
Balériaux, D., Matos, C. & De Greef, D. Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA. Neuroradiology 35, 490–494 (1993). https://doi.org/10.1007/BF00588702
- Magnetic resonance imaging
- Contrast enhancement